{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:26:04Z","timestamp":1783416364534,"version":"3.54.6"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Beijing Talents Funds","award":["2017000021469G281"],"award-info":[{"award-number":["2017000021469G281"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,22]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      This study aimed to evaluate the efficacy and safety of anlotinib combined with limb salvage therapy in patients with osteosarcoma after chemotherapy failure. A retrospective study was conducted on 46 eligible osteosarcoma patients who failed chemotherapy, admitted to our hospital from October 2021 to December 2022. They were divided into 2 groups: 28 patients in the anlotinib combined with limb salvage surgery group (combined group) and 18 patients in the limb salvage surgery alone group (surgery group). The primary endpoint was progression-free survival (PFS); secondary endpoints included objective response rate, disease control rate, overall survival (OS), and adverse events (AEs). Therapeutic efficacy was evaluated by response evaluation criteria in solid tumors 1.1, and AEs were graded by common terminology criteria for adverse events v4.0. The median PFS in the combined group was 4.8 months (95% confidence interval: 3.5\u20137.1 months), significantly longer than that in the surgery group (2.8 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.05). The objective response rate and disease control rate in the combined group were 39.29% and 67.86%, respectively, which were numerically higher than those in the surgery group (16.67% and 38.89%). Common AEs in the combined group included anorexia, leukopenia, and elevated transaminases, with significantly higher incidence than in the surgery group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.05); hypothyroidism was more common in the surgery group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.05). Anlotinib combined with limb salvage therapy shows favorable efficacy in prolonging PFS and improving disease control in chemotherapy-refractory osteosarcoma patients, with manageable adverse reactions. It may be a viable option for such patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048632","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T17:01:32Z","timestamp":1779469292000},"page":"e48632","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A retrospective study on the efficacy and safety of anlotinib combined with limb salvage therapy for osteosarcoma after chemotherapy failure"],"prefix":"10.1097","volume":"105","author":[{"given":"Yang","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Orthopedic Oncology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoyang","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Oncology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Oncology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Oncology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9178-4377","authenticated-orcid":false,"given":"Weifeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Oncology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260707","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11912-021-01053-7","article-title":"Update on osteosarcoma.","volume":"23","author":"Belayneh","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"R2-20260707","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.3390\/cells10102684","article-title":"Osteosarcoma in adolescents and young adults.","volume":"10","author":"Lee","year":"2021","journal-title":"Cells"},{"key":"R3-20260707","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","article-title":"Osteosarcoma: current treatment and a collaborative pathway to success.","volume":"33","author":"Isakoff","year":"2015","journal-title":"J Clin Oncol"},{"key":"R4-20260707","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra2103423","article-title":"New horizons in the treatment of osteosarcoma.","volume":"385","author":"Meltzer","year":"2021","journal-title":"N Engl J Med"},{"key":"R5-20260707","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/bph.15713","article-title":"Osteosarcoma mechanobiology and therapeutic targets.","volume":"179","author":"Shoaib","year":"2022","journal-title":"Br J Pharmacol"},{"key":"R6-20260707","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.4103\/0366-6999.187849","article-title":"Is there a reliable method to predict the limb length discrepancy after chemotherapy and limb salvage surgery in children with osteosarcoma?","volume":"129","author":"Li","year":"2016","journal-title":"Chin Med J (Engl)"},{"key":"R7-20260707","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1186\/s12885-020-07502-z","article-title":"Limb salvage versus amputation in patients with osteosarcoma of the extremities: an update in the modern era using the National Cancer Database.","volume":"20","author":"Evans","year":"2020","journal-title":"BMC Cancer"},{"key":"R8-20260707","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.3390\/ijms21186885","article-title":"Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: a review of current and future strategies.","volume":"21","author":"Lilienthal","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R9-20260707","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management.","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R10-20260707","first-page":"1","article-title":"Monotherapy vs combination therapy evaluation of FDA-approved TKIs targeting PDGFR for the treatment of thyroid cancer.","volume":"44","author":"Parveen","year":"2025","journal-title":"J Biomol Struct Dyn"},{"key":"R11-20260707","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41392-024-02121-7","article-title":"AXL signaling in cancer: from molecular insights to targeted therapies.","volume":"10","author":"Yadav","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"R12-20260707","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/jim-2017-000531","article-title":"Tumor histopathological response to neoadjuvant chemotherapy in childhood solid malignancies: is it still impressive?","volume":"66","author":"Hanafy","year":"2018","journal-title":"J Investig Med"},{"key":"R13-20260707","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1080\/14737140.2019.1686979","article-title":"The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.","volume":"19","author":"Wilding","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"R14-20260707","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1200\/JCO.22.02459","article-title":"Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: a real-world report from the cancer therapy using checkpoint inhibitors in people living With HIV-international (CATCH-IT) consortium.","volume":"41","author":"El-Zarif","year":"2023","journal-title":"J Clin Oncol"},{"key":"R15-20260707","doi-asserted-by":"crossref","first-page":"20220339","DOI":"10.1259\/bjr.20220339","article-title":"The lung cancers: staging and response, CT, (18)F-FDG PET\/CT, MRI, DWI: review and new perspectives.","volume":"96","author":"Owens","year":"2023","journal-title":"Br J Radiol"},{"key":"R16-20260707","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study.","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:00:50Z","timestamp":1783414850000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":16,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048632","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2025-12-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}